A Boston-based drug discovery firm has announced a major new financial agreement with a Chinese pharmaceutical company aimed at tackling diseases of the central nervous system.
Insilico Medicine said that China Medical System will provide up to roughly 1.2 billion yuan — equivalent to approximately $177 million — in milestone payments as part of a joint research and development program in the central nervous system disease field.
According to a statement from Insilico, the collaboration is focused on a “mass-market indication in central nervous system” conditions. The company added that both parties will “jointly advance the co-development of the R&D programme.”
This is not the first time the two companies have worked together. Insilico has previously announced partnerships with China Medical System covering disease areas that include both central nervous system and autoimmune conditions.
When asked about the specific disease targeted by this latest collaboration, China Medical System did not immediately provide a response.
